Publications by authors named "Patrick G Gavin"

Claim this Profile
E
Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Patrick G Gavin

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.
Patrick G Gavin, Erik L Allman, David Jayne, Eduardo Mysler, Zahir Amoura

RMD Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
Tina Baker, Hoda Sharifian, Paul J Newcombe, Patrick G Gavin, Mark N Lazarus

Ann Rheum Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Patrick G Gavin

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omic interactions in the gut of children at the onset of islet autoimmunity.
Patrick G Gavin, Ki Wook Kim, Maria E Craig, Michelle M Hill, Emma E Hamilton-Williams

Microbiome· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metaproteomic sample preparation methods bias the recovery of host and microbial proteins according to taxa and cellular compartment.
Patrick G Gavin, Justin Wong, Dorothy Loo, Danny Zipris, Michelle M Hill

J Proteomics· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib-Plus-Cetuximab in Quadruple-WT () Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Samuel A Jacobs, James J Lee, Thomas J George, James L Wade, Philip J Stella, Patrick G Gavin

Clin Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An acetate-yielding diet imprints an immune and anti-microbial programme against enteric infection.
Yu Anne Yap, Keiran H McLeod, Craig I McKenzie, Patrick G Gavin, Mercedes Davalos-Salas

Clin Transl Immunology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831.
Katherine L Pogue-Geile, Nan Song, Daniel J Serie, Ying Wang, Patrick G Gavin

JNCI Cancer Spectr· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, Patrick G Gavin

Breast Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
Saranya Chumsri, Zhuo Li, Daniel J Serie, Afshin Mashadi-Hossein, Gerardo Colon-Otero, Patrick G Gavin

J Clin Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer.
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, Patrick G Gavin

Breast Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.
Rim S Kim, Nan Song, Patrick G Gavin, Roberto Salgado, Hanna Bandos

J Natl Cancer Inst· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The gut microbiota in type 1 diabetes: friend or foe?
Patrick G Gavin, Emma E Hamilton-Williams

Curr Opin Endocrinol Diabetes Obes· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.
Rekha Pal, Ning Wei, Nan Song, Shaoyu Wu, Rim S Kim, Patrick G Gavin

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intestinal Metaproteomics Reveals Host-Microbiota Interactions in Subjects at Risk for Type 1 Diabetes.
Patrick G Gavin, Jane A Mullaney, Dorothy Loo, Kim-Anh Lê Cao, Peter A Gottlieb

Diabetes Care· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).
S Rim Kim, Nan Song, Greg Yothers, Patrick G Gavin, Carmen J Allegra

Br J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Type 1 diabetes susceptibility alleles are associated with distinct alterations in the gut microbiota.
Jane A Mullaney, Juliette E Stephens, Mary-Ellen Costello, Cai Fong, Brooke E Geeling, Patrick G Gavin

Microbiome· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 1 diabetes susceptibility alleles are associated with distinct alterations in the gut microbiota.
Jane A Mullaney, Juliette E Stephens, Mary-Ellen Costello, Cai Fong, Brooke E Geeling, Patrick G Gavin

Microbiome· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Immunoglobulin G Fragment C Receptor Polymorphisms in Solid Tumors-Reply.
S Rim Kim, Patrick G Gavin, Katherine Pogue-Geile

JAMA Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
Patrick G Gavin, Nan Song, S Rim Kim, Corey Lipchik, Nicole L Johnson

JAMA Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Nan Song, Katherine L Pogue-Geile, Patrick G Gavin, Greg Yothers, S Rim Kim

JAMA Oncol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls.
Patrick G Gavin, Nan Song, S Rim Kim, Katherine L Pogue-Geile, Soonmyung Paik

J Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.
Katherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, Patrick G Gavin, Seong-Rim Kim

J Clin Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, Noriko Tanaka, Hanna Bandos, Patrick G Gavin

J Natl Cancer Inst· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis